Dr Nathan Papa

Role: Research Methodologist

Selected publications

See all publications

2026
European Urology10.1016/j.eururo.2026.03.001
Prospective Comparison of Copper [Cu]SAR-bisPSMA vs Gallium[Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).
Sobia Khan, Nathan Papa, Andrew Kneebone, Thomas Eade, Narjess Ayati, Andrew Nguyen, Keith Wong, Jeff Chen, Bao Ho, Jordan Idiare, George Sidhom, Matthew J Roberts, James Thompson, Shikha Sharma, Shraddha Weir, Katrina Devitt, Raji Kooner, Hester Lieng, Kris Rasiah, Joanna Olphert, Jeremy de Leon, George Hruby, Phillip Stricker, Louise Emmett
2026
BJU International10.1111/bju.70183
Non-significant does not mean uninformative - but poor reporting can be misleading.
Sigrid V Carlsson, Tobias Klatte, Nathan Papa
2025
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine10.2967/jnumed.125.270804
Prognostic Value of Initial Imaging and PSA Change with [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.
David C Chen, James P Buteau, Nathan Papa, Tim Akhurst, Ramin Alipour, Neeraja Bollampally, Anthony Cardin, Michal Eifer, Sebastián Casanueva Eliceiry, Price Jackson, Kerry Jewell, Raghava Kashyap, Grace Kong, Louise Kostos, Aravind Ravi Kumar, Lachlan McIntosh, Elizabeth Medhurst, Javad Saghebi, Shahneen Sandhu, Declan G Murphy, Ben Tran, Arun A Azad, Michael S Hofman
2025
The Journal of Urology10.1097/JU.0000000000004734
The Blind Spot of Prostate-Specific Membrane Antigen Positron Emission Tomography Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer.
David C Chen, Zein Alhamdani, Nathan Papa, Edward Shen, Natalia Kovaleva, Maggie Gao, Louise Emmett, Michael S Hofman, Andrew Ryan, Andrew M Scott, Sze Ting Lee, Nathan Lawrentschuk, Marlon L Perera, Damien M Bolton
2025
The Lancet. Oncology10.1016/S1470-2045(25)00339-0
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Narjess Ayati, Claire Niu, Michael S Hofman, Andrew James Martin, Hayley Thomas, Ian D Davis, Martin R Stockler,

See all Garvan publications

Explore our research

Our impact

Our people

News and resources

About us

Support Us

Dr Nathan Papa

Selected publications

Prospective Comparison of Copper [Cu]SAR-bisPSMA vs Gallium[Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).

Non-significant does not mean uninformative - but poor reporting can be misleading.

Prognostic Value of Initial Imaging and PSA Change with [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.

The Blind Spot of Prostate-Specific Membrane Antigen Positron Emission Tomography Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer.

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.